
|Articles|August 1, 2003
New overactive bladder drugs aim for less side effects
Chicago-Pharmacologic treatment of overactive bladder-once the private domain of only two or three agents-is about to expand significantly, providing urologists with a number of new therapeutic options.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
3
Study suggests potential diuretic effect with nadofaragene firadenovec
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











